CA1073358A
Expired / Lapsed
CA
⏱️ 0.0 years remaining
Sustained release formulations
Assignee: F Hoffmann La Roche AG
•
Filing: 1976-03-16
•
Granted: 1980-03-11
•
Expires: 1996-03-16
Abstract
Abstract Abstract A novel sustained release formulation for oral administration in solid dosage forms such as tablets and capsules is disclosed. The formulation is hydrodynamically balanced to be buoyant in gastric juice thereby remaining in the stomach for an extended period of time.
Inventors
- 👤 Prabhakar R. Sheth
- 👤 Jacques L. Tossounian
Bibliographic Details
Application Number
—
Jurisdiction
CA
Data Source
google_patents
Last Synchronized
2026-10-23 03:29
CPC Classifications
A; A61; A61K; A61K9/00; A61K9/0012; A61K9/0053; A61K9/0065
Claims Analysis
Total Claims: 5
Claim 1
Independent Claim
174 words
1, A sustained release pharmaceutical formulation containing as the active ingredient a benzodiazepine selected from the group consisting of chlordiazepoxide and diazepam, one or more antacid compounds or acetylsalicylic acid, said formulation being hydrodynamically balanced so that, upon contact with gastric fluid, said formulation acquires and maintains a bulk density of less than 1 thereby being buoyant in said fluid and remaining buoyant in the gastric fluid of the stomach until substantially all of the active ingredient contained therein has been released, said for-mulation comprising a homogeneous mixture of said active ingredient; from 0 % to 80 % by weight of therapeutically inert, pharmaceutically acceptable adjunct materials; from 0 % to 60 % by weight of a fatty material having a specific gravity of less than 1 and from 20 % by weight to 75 % by weight of one or a mixture of hydrocolloids selected from the group consisting of methyl cellulose, hydroxypropylcellulose, hydroxypropylmethylcellulose, hydroxyethylcellulose and sodium-carboxymethylcellulose to provide upon contact with gastric fluid, a water-im-permeable barrier on the surface of said formulation.
Claim 2
Dependent Claim
174 words
1, A sustained release pharmaceutical formulation containing as the active ingredient a benzodiazepine selected from the group consisting of chlordiazepoxide and diazepam, one or more antacid compounds or acetylsalicylic acid, said formulation being hydrodynamically balanced so that, upon contact with gastric fluid, said formulation acquires and maintains a bulk density of less than 1 thereby being buoyant in said fluid and remaining buoyant in the gastric fluid of the stomach until substantially all of the active ingredient contained therein has been released, said for-mulation comprising a homogeneous mixture of said active ingredient; from 0 % to 80 % by weight of therapeutically inert, pharmaceutically acceptable adjunct materials; from 0 % to 60 % by weight of a fatty material having a specific gravity of less than 1 and from 20 % by weight to 75 % by weight of one or a mixture of hydrocolloids selected from the group consisting of methyl cellulose, hydroxypropylcellulose, hydroxypropylmethylcellulose, hydroxyethylcellulose and sodium-carboxymethylcellulose to provide upon contact with gastric fluid, a water-im-permeable barrier on the surface of said formulation.
Claim 3
Dependent Claim
84 words
A sustained release formulation according to claim 1, which is a capsule containing as the active ingredient a benzodiazepine selected from the group consisting of chlordiazepoxide and diazepam, said capsule comprising a finely particulate homogeneous mixture of said benzodiaze-pine; from 5 % by weight to 60 % by weight of said adjunct materials; from 0 % to 60 % by weight of said fatty material and from 20 % by weight to 75 % by weight of one or a mix-ture of said hydrocolloids.
Claim 4
Dependent Claim
176 words
A sustained release formulation according to claim 1, consisting of a two-layered tablet comprising: a first layer containing one or more antacid substances and therapeutically inert pharmaceutically acceptable adjunct materials free of sustained release ingredients; and a second layer containing as the active ingredient , one or more antacid compounds, said tablet being hydro-dynamically balanced so that, upon contact with gastric fluid, said second layer acquires and maintains a bulk density of less than one thereby being buoyant in said fluid and remaining buoyant in the gastric fluid of the stomach until substantially all of the antacid compounds contained therein have been released therefrom, said second layer comprising a homogeneous mixture of said antacid compounds, from 0 % to 80 % by weight of said adjunct materials, and from 20 % by weight to 75 by weight of one or a mixture of said hydrocolloids to provide, upon contact with gastric fluid, a water im-permeable barrier on the surface of said second layer, said tablet being compressed to a hardness of from 12 to 14 S.C.U.
Claim 5
Dependent Claim
71 words
A sustained release formulation according to claim 1, which is a tablet containing as the active ingredient acetylsalicylic acid, said tablet comprising a homogeneous mixture of acetylsalicyclic acid; 0 % to 80 % by weight of said adjunct materials and from 20 % by weight to 75 % by weight of one or a mixture of said hydrocolloids, said tablet being compressed to a hardness of from 5 to 6 S.C.U.
References Cited (Backward Citations)
No citation records indexed.
USPTO Annuity & Maintenance Windows
Maintenance schedule is calculated for granted US utility patents.